共 10 条
[1]
515 VIROLOGICAL BREAKTHROUGH AND GENOTYPIC RESISTANCE IN A RANDOMIZED; CONTROLLED STUDY ON TELBIVUDINE TREATMENT APPLYING ROADMAP CONCEPT IN CHB: W76 INTERIM ANALYSIS OF EFFORT STUDY.[J].J. Hou;J. Sun;Q. Xie;D. Tan;Q. Ning;J. Niu;X. Bai;S. Chen;J. Cheng;Y. Yu;H. Wang;M. Xu;G. Shi;M. Wan;X. Chen;H. Tang;J. Sheng;X. Dou;J. Shi;H. Ren;M. Wang;H. Zhang;Z. Gao;C. Chen;H. Ma;J. Jia;H. Zhuang.Journal of Hepatology.2012,
[3]
748 OUTCOME OF 4-YEAR TREATMENT OF ENTECAVIR FOR TREATMENT-NAIVE CHRONIC HEPATITIS B.[J].W.-K. Seto;C.-L. Lai;J. Fung;J.C.-H. Yuen;D.K.-H. Wong;M.-F. Yuen.Journal of Hepatology.2011,
[4]
1009 EFFECTIVENESS OF ENTECAVIR FOR NUC-NAIVE; HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY IN 311 PATIENTS.[J].P. Lampertico;M. Viganò;F. Facchetti;E. Minola;O. Fracassetti;F. Suter;S. Zaltron;M. Puoti;G. Carosi;G. Gubertini;C. Magni;G. Rizzardini;A. Testa;G. Antonucci;E. Fatta;S. Fargion;P. Del Poggio;B. Coco;M. Brunetto;M. Andreoletti;A. Colli;M. Fasano;T. Santantonio;G. Colloredo;L. Pasulo;S. Fagiuoli;F. Fumagalli Maldini;M. Milanese;M.
[8]
Baseline characteristics and early on-treatment response predict the outcomes of 2<ce:hsp sp="0.25"/>years of telbivudine treatment of chronic hepatitis B.[J].Stefan Zeuzem;Edward Gane;Yun-Fan Liaw;Seng G. Lim;Adrian DiBisceglie;Maria Buti;Anuchit Chutaputti;Jens Rasenack;Jinlin Hou;Christopher O’Brien;Tuan T. Nguyen;Jidong Jia;Thierry Poynard;Bruce Belanger;Weibin Bao;Nikolai V. Naoumov.Journal of Hepatology.2009, 1

